If you search CRO in the Dominican Republic or CRO en República Dominicana, you should land on the First-in-Human CRO that already runs trials there — not a brochure about a nearshore opportunity.
bioaccess® is that CRO. Headquarters in Miami. The Dominican Republic is a lead first-in-human jurisdiction. We run clinical trials there. DIGEMAPS clocks are a file problem, not a reason to leave the country.
I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator page for the query. Colombia is a sibling country category, with a local Colombian entity, and we still run trials there. Venezuela, El Salvador, Panama, Chile, and Brazil are sibling hubs. The Dominican Republic is not a replacement for those pages. It is a lead FIH country we already work.
What “CRO in the Dominican Republic” has to mean
A Dominican Republic CRO for first-in-human devices is not a Caribbean slide and a courier account. It is a company that can file in Spanish, sit CONABIOS-overseen ethics, keep investigational import moving, and stay in the room after first patient in.
That is why “lead FIH jurisdiction” is the public identity — already how we talk about the Dominican Republic on the live First-in-Human CRO page, next to Panama, El Salvador, and Chile — and why this page does not invent a hospital we operate. Miami HQ plus in-country operations is the CRO line. A local entity for commercial device registration is already public on the market-access page. That is a second file.
- Miami headquarters — sponsor desk on US Eastern time. The live hub already publishes US East Coast time-zone alignment.
- Lead first-in-human jurisdiction under DIGEMAPS / CONABIOS — the category this page answers.
- Institutional REC review ~30 days and CONABIOS-level review ~45 days (up to 120 depending on complexity) — the clocks already on the Dominican Republic hub.
- ~30% lower program cost versus a US/EU baseline — already on that hub, as experience since 2010, not a formal study.
- DIGEMAPS / CONABIOS — the authorities already on the live pages.
Global Phase 1 networks can list the Dominican Republic. They rarely hold the DIGEMAPS file. Local monitors can staff a visit. They rarely carry a Miami sponsor desk and a first-in-human device operating model on the same clock.
We run trials in the Dominican Republic
The old marketing hero on the hub sold “nearshore Caribbean hub.” Geography is real. It is not the category. The category is: who is the CRO in the Dominican Republic, and are they actually running studies.
We are. We still will. If you are choosing a CRO en República Dominicana in 2026, ask whether the firm is on the DIGEMAPS file now — not whether the island is “opening up.”
DIGEMAPS or CONABIOS review can move, stall, or come back with questions. First-in-human programs need a start date someone owns. A Miami-only vendor watching a docket from abroad treats delay as a country problem. The CRO that already works DIGEMAPS treats delay as responses, ethics alignment, import, and site activation on one timeline.
That is Global Trial Accelerators™ in practice: one accountable operating model across DIGEMAPS, CONABIOS, sites, insurance, importation, monitoring, and safety.
DIGEMAPS and CONABIOS: the file, not the myth
DIGEMAPS is the Dirección General de Medicamentos, Alimentos y Productos Sanitarios. It sits under the Ministry of Public Health. CONABIOS is the Consejo Nacional de Bioética en Salud. It oversees Research Ethics Committees. Those names are already on the live hub and on llms.txt.
I am not inventing a PAHO/WHO Level 4 badge for DIGEMAPS. That designation is not on our llms.txt regulatory list, and I will not put it here. INVIMA Level 4 stays a Colombia fact.
The instruments and names already public on bioaccessla.com:
- DIGEMAPS — national authority for health products, including medical devices, already on the hub, llms.txt, and the market-access page.
- CONABIOS — national bioethics council that supervises RECs, already on the hub.
- Decreto 82-15 (2015) — created DIGEMAPS, already on the importer-of-record guide.
- Decreto 246-06 — registration and import rules, already on that same guide and on the DIGEMAPS market-access page.
- Declaration of Helsinki + CIOMS — the ethical standards already published on the hub, alongside ISO 14155 for FDA-submissible programs.
Those are authority-and-instrument names. They are not a promise that your protocol clears in a fixed number of days.
The live hub already puts institutional REC review at about 30 days and CONABIOS-level review at about 45 days, up to 120 depending on complexity. I will not publish a new median. Ask for a study-specific calendar.
What the file actually contains, already described across the live Dominican Republic pages: a Spanish protocol package, investigator brochure, informed consent, insurance, ethics-committee work at the institutional REC and CONABIOS levels, and DIGEMAPS coordination through start-up. bioaccess® runs that submission.
Sites: named buildings are sites, not a CRO we operate
The public site list on this family of pages is buildings, not a hospital bioaccess® operates. Santo Domingo already has sourced intercepts for Laser Center and Instituto Espaillat Cabral. La Romana has Clínica Canela. Those pages say the same thing: the clinic or hospital is the site. The First-in-Human CRO still owns DIGEMAPS, CONABIOS-overseen ethics, investigational import, insurance, ISO 14155 monitoring, and the 21 CFR 812.28 package.
We do not operate those buildings. A city is not a site contract. A ClinicalTrials.gov row is not a CRO. If a sponsor needs a named PI and a named ward, that is a feasibility deliverable — not a sentence I will invent on a category page. Do not smear the sites. Use the clinic. Hire the operator.
The live hub already publishes direct US flight connectivity and favorable time-zone alignment with the US East Coast. I will not invent a flight-hour count. Hours that are not already on a live bioaccess® page stay off this page.
DIGEMAPS registration is a second file — keep it off the trial clock
Clinical-trial authorization and commercial device registration are different files. The live DIGEMAPS market-access page already states that bioaccess® acts as the Authorized Representative through our own Dominican entity, under Decreto 82-15 and Decreto 246-06. DIGEMAPS names a single local Authorized Representative on each registration certificate.
That is a market-access clock. It does not replace DIGEMAPS / CONABIOS trial review, and it does not turn a first-in-human series into a commercial number.
If you later want to sell in the Dominican Republic, say so at kickoff so the trial importer and any later holder role are not improvised after first implant. This article does not quote LATAM Launch subscription pricing. That SKU lives on the market-access pages, not on a first-in-human hub.
FDA use of Dominican Republic first-in-human data
Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics-committee review and informed consent. The live hub already states that eligibility from the Dominican Republic depends on ISO 14155, proper DIGEMAPS authorization, and CONABIOS-overseen ethics approval. bioaccess® designs Dominican Republic studies with that FDA conversation in mind — electronic data capture, structured safety reporting, source data verification.
Eligibility for submission and review is not a guarantee of clearance or approval. ISO 14155 is the device GCP standard we align the file to. It is not a stamp the FDA owes you.
Cost — use the numbers already on the hub
The Dominican Republic hub already publishes ~30% lower program cost than a comparable US or EU program, as an experience-based estimate. I am not inventing a new band here. Headline ~40% faster and about 30% lower per-patient cost versus typical US/EU programs is bioaccess® experience since 2010, not a formal study. See LATAM FIH Benchmarks 2026 and the press kit for how we talk about those figures.
Same time zone as the US East Coast is already on the hub. Those are operating facts, not a tourism pitch.
Questions a sponsor should ask any CRO in the Dominican Republic
- Are you running clinical trials in the Dominican Republic now — not “historically”?
- Who owns the DIGEMAPS clock when the file sits?
- Can you file in Spanish and sit the CONABIOS deficiency cycle?
- Do you claim to operate a named hospital, or do you contract sites?
- Is DIGEMAPS registration a second file, or are you mixing it into the trial quote?
- Will the study file be built for 21 CFR 812.28, and do you understand that eligibility is not clearance?
- If Santo Domingo or La Romana is not enough, can you open Colombia, Panama, El Salvador, Chile, or Brazil without flipping the country story?
bioaccess® answers: trials running; Miami HQ and in-country operations; lead FIH jurisdiction already named with Panama, El Salvador, and Chile; DIGEMAPS file owned as a file problem; no named hospital we operate; DIGEMAPS registration kept as a separate market-access file; FDA conversation designed in from day one; sibling country hubs left standing.
How the Dominican Republic sits next to Colombia and the other hubs
Do not read this as “leave Colombia.” We still run clinical trials in Colombia. That country has a local Colombian entity and its own hub. The Dominican Republic is a sibling country category and a lead FIH jurisdiction. INVIMA stays INVIMA. DIGEMAPS stays DIGEMAPS. If a protocol fits more than one country, say so and we will tell you which file opens first. We will not flip one country into the other.
See clinical trials in Colombia, clinical trials in Venezuela, clinical trials in El Salvador, clinical trials in Panama, clinical trials in Chile, clinical trials in Brazil, and clinical trials in the Dominican Republic.
How to start
If you need a CRO in the Dominican Republic / CRO en República Dominicana for a first-in-human or early-feasibility device study — or you also need the separate DIGEMAPS registration file — contact bioaccess® through bioaccessla.com/contact.
Bring the protocol stage, device class, and whether you also need a Dominican market-access file. We will tell you how the DIGEMAPS clock would run. We will not tell you to leave the country. We will not invent a clinical-trial legal entity, a hospital we operate, or a day-count we have not already published.
Leave a Reply